The optimism about these results is not only because of NVX-CoV2373’s efficacy against the emerging variants, which have created concerns about viral escape from vaccines, but also because Novavax’s candidate works in a very different way to the already-approved Covid-19 vaccines. Importantly, Erck noted that Novavax’s vaccine demonstrated “significant clinical efficacy against both the rapidly emerging UK and South Africa variants”, as well as previous dominant Covid-19 variants, making it the first vaccine to do this in clinical trials.įaculty of Pharmaceutical Medicine chair of policy and community Dr Gillies O’Bryan-Tear said: “This is yet more good news for the effort to develop a range of vaccines against Covid-19, and is the first clinical data suggesting efficacy against the current UK and South Africa variants.” In an investor conference call, the company’s CEO Stanley Erck described the efficacy of NVX-CoV2373 against Covid-19 as profound. Novavax also published promising results from a Phase IIb study of the vaccine in South Africa. This study was carried out in partnership with the UK’s Vaccine Taskforce, which has also negotiated access to 60 million doses to be manufactured in Stockton-on-Tees. Late in January, Novavax published positive interim results from its UK Phase III trial, in which NVX-CoV2373 was broadly found to be 89.3% effective at preventing Covid-19 infection. Now a fourth vaccine has taken to the stage: Novavax’s two-dose protein subunit-based candidate NVX-CoV2373 containing a proprietary Matrix-M adjuvant. Please check your email to download the Whitepaper. What are the potential growth opportunities?.How might the Chinese government react?.Spotlight on Shanghai: what is the situation there?.What is the effect of lockdowns on Chinese ports?.What is the effect of lockdowns on foodservice?. ![]() ![]() Which multinational companies have been affected?.Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains.Ĭhina’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn.
0 Comments
Leave a Reply. |